Research Paper Volume 11, Issue 23 pp 11490—11503

Conditional disease-free survival in high-risk renal cell carcinoma treated with sunitinib

Figure 2. (A) The smooth estimate of HR for relapse among high-risk ccRCC patients treated with adjuvant sunitinib or placebo. (B) Conditional probability of surviving an additional 3 disease-free year at various time points in very high-risk (T3, Fuhrman grade 2, ECOG Performance Status≥1; or T4 or N1) and high-risk group. The dots represent the probability point estimates, and the vertical bars represent the 95% CIs of the corresponding point estimates.